123 related articles for article (PubMed ID: 15671135)
1. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.
Dunkley MJ; Reveley MA
J Psychopharmacol; 2005 Jan; 19(1):97-101. PubMed ID: 15671135
[TBL] [Abstract][Full Text] [Related]
2. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
6. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.
Sirota P; Pannet I; Koren A; Tchernichovsky E
Hum Psychopharmacol; 2006 Jun; 21(4):227-34. PubMed ID: 16783811
[TBL] [Abstract][Full Text] [Related]
7. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
9. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
10. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
11. Prolactin elevation with quetiapine.
Alexiadis M; Whitehorn D; Woodley H; Kopala L
Am J Psychiatry; 2002 Sep; 159(9):1608-9. PubMed ID: 12202292
[No Abstract] [Full Text] [Related]
12. Diabetes mellitus during olanzapine and quetiapine treatment in Japan.
Cohen D
J Clin Psychiatry; 2005 Feb; 66(2):265-6; author reply 266-7. PubMed ID: 15705015
[No Abstract] [Full Text] [Related]
13. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
Haddad PM; Wieck A
Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
[TBL] [Abstract][Full Text] [Related]
14. Early use of clozapine for poorly responding first-episode psychosis.
Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Lambert M; Haro JM; Novick D; Edgell ET; Kennedy L; Ratcliffe M; Naber D
Acta Psychiatr Scand; 2005 Mar; 111(3):232-43. PubMed ID: 15701108
[TBL] [Abstract][Full Text] [Related]
16. The paradox of quetiapine in obsessive-compulsive disorder.
Tranulis C; Potvin S; Gourgue M; Leblanc G; Mancini-Marie A; Stip E
CNS Spectr; 2005 May; 10(5):356-61. PubMed ID: 15858452
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
18. [Current pharmacotherapy of schizophrenia].
Bitter I
Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine in the successful combination treatment of an assaultive patient with treatment-resistant schizoaffective disorder.
Post DE
Behav Med; 2007; 33(1):11-4. PubMed ID: 17517541
[TBL] [Abstract][Full Text] [Related]
20. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
